The utility of the Mattis Dementia Rating Scale in Parkinson's disease mild cognitive impairment

被引:39
|
作者
Pirogovsky, Eva [1 ,2 ]
Schiehser, Dawn M. [1 ,2 ]
Litvan, Irene [3 ]
Obtera, Kristalyn M. [1 ]
Burke, Mathes M. [1 ]
Lessig, Stephanie L. [1 ,3 ]
Song, David D. [1 ,3 ]
Liu, Lin [4 ]
Filoteo, J. Vincent [1 ,2 ]
机构
[1] San Diego Hlth Care Syst, Vet Affairs, San Diego, CA USA
[2] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
[3] Univ Calif San Diego, Movement Disorder Ctr, Dept Neurosci, San Diego, CA 92103 USA
[4] Univ Calif San Diego, Div Biostat & Bioinformat, San Diego, CA 92103 USA
关键词
Parkinson's disease-mild cognitive impairment; Mattis Dementia Rating Scale; Optimal cuttoff scores; DIAGNOSTIC-CRITERIA; VALIDITY; QUESTIONNAIRE; RELIABILITY;
D O I
10.1016/j.parkreldis.2014.03.010
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: The Movement Disorders Society (MDS) recently proposed guidelines for diagnosis of mild cognitive impairment in Parkinson's disease (PD-MCI) that includes two assessment levels: abbreviated (Level I) and comprehensive (Level II). The aim of this study was to determine the utility of the Mattis Dementia Rating Scale (MDRS), a recommended Level I test, for detecting Level II PD-MCI diagnosis. Methods: The study sample included 30 patients diagnosed with PD-MCI based on Level II MDS criteria and 68 PD patients with normal cognition (PD-NC). Receiver operator curve (ROC) analyses were generated to measure the sensitivity and specificity of various MDRS cutoff scores. To examine the utility of the MDRS as a screening tool, the optimal cutoff point was defined as the lowest value providing >= 80% sensitivity. For use of the MDRS as a diagnostic tool, the optimal cutoff point was defined as the highest value providing >= 80% specificity. Results: ROC analyses showed that the optimal MDRS cutoff score for screening purposes and diagnostic purposes were <= 140 and <= 137, respectively. However, an examination of sensitivity/specificity values for the screening cutoff scores suggested that a total score of <= 139 for screening purposes yielded a better balance between sensitivity (77%) and specificity (65%). Conclusions: In a clinical setting, in which detection of PD-MCI may be important, a total MDRS score of <= 139 can be used to detect PD-MCI. In research and other settings in which diagnostic certainty is more important, a score of <= 137 may be more useful. Published by Elsevier Ltd.
引用
收藏
页码:627 / 631
页数:5
相关论文
共 50 条
  • [1] Clinical Validity of the Mattis Dementia Rating Scale in Differentiating Mild Cognitive Impairment in Parkinson's Disease and Normative Data
    Bezdicek, Ondrej
    Michalec, Jiri
    Nikolai, Tomas
    Havrankova, Petra
    Roth, Jan
    Jech, Robert
    Ruzicka, Evzen
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2015, 39 (5-6) : 303 - 311
  • [2] Is the Mattis Dementia Rating Scale appropriate to detect Mild Cognitive Impairment?
    Belaus, Anabel
    Fernandez, Luis A.
    Farias-Sarquis, Yamila
    Bueno M, Adrian M.
    REVISTA CHILENA DE NEUROPSICOLOGIA, 2015, 10 (01): : 8 - 13
  • [3] The Mattis Dementia Rating Scale (MDRS) sensitive to mild cognitive impairment?
    Matteau, Evelyne
    Jean, Leonie
    Simard, Martine
    Turgeon, Yves
    JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES, 2007, 19 (02) : 231 - 231
  • [4] Validity of the Mattis Dementia Rating Scale to Detect Mild Cognitive Impairment in Parkinson's Disease and REM Sleep Behavior Disorder
    Villeneuve, Sylvia
    Rodrigues-Brazete, Jessica
    Joncas, Steve
    Postuma, Ronald B.
    Latreille, Veronique
    Gagnon, Jean-Francois
    DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2011, 31 (03) : 210 - 217
  • [5] Mattis Dementia Rating Scale Distinguishes between Parkinson's Disease with Mild Cognitive Impairment (PD-MCI) and Amnestic-Mild Cognitive Impairment (A-MCI)
    Matteau, Evelyne
    Jean, Leonie
    Simard, Martine
    Dupre, Nicolas
    NEUROLOGY, 2009, 72 (11) : A383 - A383
  • [6] Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson's disease
    Dujardin, Kathy
    Devos, David
    Duhem, Stephane
    Destee, Alain
    Marie, Rose-Marie
    Durif, Franck
    Lacomblez, Lucette
    Touchon, Jacques
    Pollak, Pierre
    Pere, Jean-Jacques
    JOURNAL OF NEUROLOGY, 2006, 253 (09) : 1154 - 1159
  • [7] Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson’s disease
    Kathy Dujardin
    David Devos
    Stéphane Duhem
    Alain Destée
    Rose-Marie Marié
    Franck Durif
    Lucette Lacomblez
    Jacques Touchon
    Pierre Pollak
    Jean-Jacques Péré
    Journal of Neurology, 2006, 253 : 1154 - 1159
  • [8] Performance of Mattis dementia rating scale-Chinese version in patients with mild cognitive impairment and Alzheimer’s disease
    Shuxia Qian
    Keliang Chen
    Qiaobing Guan
    Qihao Guo
    BMC Neurology, 21
  • [9] Performance of Mattis dementia rating scale-Chinese version in patients with mild cognitive impairment and Alzheimer's disease
    Qian, Shuxia
    Chen, Keliang
    Guan, Qiaobing
    Guo, Qihao
    BMC NEUROLOGY, 2021, 21 (01)
  • [10] The clinical utility of the Mattis Dementia Rating Scale in assessing cognitive decline in Alzheimer's disease
    Miller, Julie M.
    Pliskin, Neil H.
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 2006, 116 (05) : 613 - 627